Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

4.03
Delayed Data
As of Nov 21
 -0.05 / -1.23%
Today’s Change
1.73
Today|||52-Week Range
9.40
-23.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$122.4M

Company Description

Conatus Pharmaceuticals, Inc. is a biotechnology company that engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.

Contact Information

Conatus Pharmaceuticals, Inc.
16745 West Bernardo Drive
San Diego California 92127-7619
P:(858) 376-2600
Investor Relations:
(858) 376-2637

Employees

Shareholders

Individual stakeholders26.23%
Other institutional21.41%
Mutual fund holders13.54%

Top Executives

Steven J. MentoPresident, Chief Executive Officer & Director
Keith W. MarshallExecutive VP, Chief Operating & Financial Officer
Alfred P. SpadaCSO, EVP-Research & Development
Michelle L. VandertieVice President-Finance
Daniel L. RipleySenior VP-Business Development & Programme